Sanjay Keswani quits Roche to head up Boston biotech

6 September 2018

Rheos Medicines, a Boston, USA, biotech developing novel medicines that modulate metabolic pathways in immune cells to treat disease, has poached an experienced big pharma R&D leader from Roche (ROG: SIX) to be its new chief executive.

The privately-held company, which was founded by Third Rock Ventures, has appointed Sanjay Keswani into the top job, with interim CEO Abbie Celniker, a partner at the venture capital firm, remaining with Rheos as the chair of its board.

"There is an immense opportunity to change the therapeutic paradigm for treating diseases that involve the immune system, and Rheos is ideally positioned to set a new standard"

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK